Unlock instant, AI-driven research and patent intelligence for your innovation.

Activation of peptide prodrugs by hK2

a technology of peptide prodrugs and hk2, which is applied in the direction of peptides, enzymology, drug compositions, etc., can solve the problems of inability to effectively treat men with metastatic prostate cancer, and the prolonged administration of effective concentrations of standard chemotherapeutic agents is usually impossibl

Inactive Publication Date: 2008-10-09
GENSPERA
View PDF25 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention provides a novel group of peptides that have specific cleavage sites for human glandular kallikrein (hK2), which is associated with cell proliferative disorders. These peptides can be used to determine the activity of hK2 in biological samples. The invention also provides a therapeutic prodrug composition that is specifically cleaved by hK2, which can inhibit its non-specific toxicity. The invention also provides methods for detecting and treating cell proliferative disorders associated with hK2 production. The invention also includes a method for imaging soft tissue and bone metastases that produce hK2."

Problems solved by technology

There is currently no effective therapy for men with metastatic prostate cancer who relapse after androgen ablation, even though numerous agents have been tested over the past thirty years.
Prolonged administration of effective concentrations of standard chemotherapeutic agents is usually not possible because of dose-limiting systemic toxicities.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Activation of peptide prodrugs by hK2
  • Activation of peptide prodrugs by hK2
  • Activation of peptide prodrugs by hK2

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production of Recombinant hK2

[0052]Recombinant hK2 was produced and purified as described in Lövgren et al., Biochem. Bioph. Res. Co., 238, 549-555 (1997). Semenogelin I and II were isolated from human semen as described previously in Malm et al., Eur. J. Biochem., 238, 48-53 (1996). The tripeptide aminomethylcoumarin (AMC) substrates Bos-Phe-Ser-Arg-AMC, Boc-Gln-Gly-Arg-AMC, H-Pro-Phe-Arg-AMC, boc-Val-Pro-Arg-AMC, H-D-Val-Leu-Lys-AMC, Tos-Gly-Pro-Arg-AMC-Tos-Gly-Pro-Lys-AMC, Z-Leu-Leu-Arg-AMC, Z-Val-Val-Arg-AMC, Z-Ala-Arg-Arg-AMC, and H-Arg-Gln-Arg-Arg-AMC were from Bachem (Bubendorf, Switzerland). The heptapeptide substrates Mu-Ala-Pro-Val-Leu-Ile-Leu-Ser-Arg-AMC and Mu-Val-Pro-Leu-Ile-Gln-Ser-Arg-AMC corresponding to the pro peptides of PSA hK2 were from Enzyme Systems Product (Livermore, Calif., USA). ACT was purified from human blood plasma as described in Christenssson et al., Eur. J. Biochem., 194, 755-63 (1990). PCI was provided by Prof. Johan Stenflo (Malmö University Hospi...

example 2

Determination of hK2 Cleavage Sites in Semenogelin I and II

[0053]Purified semenogelin I and II (40 μg), was incubated with hK2 (8 μg) in 50 mM Tris pH 7.5, 0.1 M NaCl, 0.15 M urea at 37° C. for 4 hours. The fragments generated were purified by reverse phase HPLC using a C-8 column. Elution was achieved with a 0-30% (0.25% / min.) linear acetonitrile gradient and fractions corresponding to individual peaks were collected. The amino terminal sequences of the individual peaks were determined by automated amino terminal sequencing with an Applied Biosystems 470 A gas-phase sequencer. Cleavage of either Sg I or Sg II with hK2 results in generation of a multitude of peptides. After partial separation of the peptides by reversed phase HPLC on a C-8 column we obtained sequences of four cleavage sites in Sg I and seven cleavage sites in Sg II. The semenogelins contain three types of internal repeats, as described in Lilja et al., J. Biol. Chem., 264, 1894-2000 (1989) and Lilja et al., PNAS USA...

example 3

pH Dependence of the Enzymatic Action of hK2

[0054]The pH dependence of hK2 was determined using a universal buffer composed of 29 mM citric acid, 29 mM citric acid, 29 mM KH2PO4, 29 mM boric acid 0.1 M NaCl and 0.2% BSA. The buffering range is Ph 2.4-11.8. The rate of the cleavage of the substrate I-1295 (100 μM) by 1.6 pmol hK2 was followed for 20 minutes at pH 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10.

[0055]All experiments were done close to physiological pH, at pH 7.5, which is very close to the pH optimum of hK2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
dissociation constantaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The invention provides novel peptide prodrugs that contain cleavage sites specifically cleaved by human kallikrein 2 (hK2). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. Upon cleavage of the prodrug by hK2, the therapeutic drugs are activated and exert their toxicity. Methods for treating cell proliferative disorders are also featured in the invention.

Description

FIELD OF THE INVENTION[0001]This invention relates generally to the targeted activation of biologically active materials to cells that produce human glandular kallikrein (hK2) and more specifically to hK2-specific peptides substrates that can act as drug carriers. In addition it relates to prodrugs consisting of a peptide covalently coupled to a cytotoxic drug such that the peptide-drug bond can be hydrolyzed by hK-2. The coupling of the peptide to the cytotoxic drug creates an inactive prodrug that can only become activated at sites where enzymatically active hK-2 is being produced.BACKGROUND OF THE INVENTION[0002]There is currently no effective therapy for men with metastatic prostate cancer who relapse after androgen ablation, even though numerous agents have been tested over the past thirty years. Prolonged administration of effective concentrations of standard chemotherapeutic agents is usually not possible because of dose-limiting systemic toxicities.[0003]Human Glandular Kall...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K49/00C07K7/06C07K7/08C07K5/00C07K9/00C07K16/00C07H21/00A61P35/00A61K47/42A61K31/343A61K31/7052A61K31/704C12Q1/02A61K47/48C07K14/47
CPCA61K47/48338C07K7/06C07K14/47C12N9/6445A61K47/65A61P35/00
Inventor DENMEADE, SAMUEL R.ISAACS, JOHN T.LILJA, HANS
Owner GENSPERA